SCHEMBL2650725

SCHEMBL2650725

CCCCCCc1c(C(C)C)cc(C(C)C)c(C(C)O)c1-c1ccc(F)cc1

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 19/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647530 0.99 GCGR (0.83) GCGR
SCHEMBL2654164 0.99 GCGR (0.83) GCGR
SCHEMBL2648146 0.95 GCGR (0.85) GCGR
SCHEMBL2647841 0.90 GCGR (0.65) GCGR
SCHEMBL105891 0.90 GCGR (1.00) GCGR
SCHEMBL30661851 0.90 GCGR (1.00) GCGR
SCHEMBL2648690 0.89 GCGR (0.67) GCGR
SCHEMBL2647745 0.88 GCGR (0.62) GCGR
SCHEMBL2648322 0.88 GCGR (0.62) GCGR
SCHEMBL2648866 0.86 GCGR (0.64) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US claimed
EP-0934274-A1 SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS Bayer Corporation (US) 1999-08-11 EP claimed
WO-1998004528-A2 SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS BAYER CORPORATION (US) 1998-02-05 WO claimed
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed